Follow us for updates
© 2022
Read the Story →

First Pill for Alopecia Treatment Gets Approved in U.S.

Treatment for severe alopecia.
by Agence France Presse
Jun 14, 2022
Photo/s: @jadapinkettsmith/Instagram

WASHINGTON -- The Food and Drug Administration on Monday approved a drug called baricitinib as the first oral tablet for  treating severe alopecia areata, an autoimmune disorder affecting more than 300,000 people in the United States every year.

Alopecia causes either temporary or permanent patchy hair loss that can affect any hair-bearing site of the body, leading to emotional distress. The condition has come to the fore recently through high-profile cases including Hollywood actress Jada Pinkett Smith and congresswoman Ayanna Pressley.


What is Alopecia, and What Causes It?

Hair Loss is No Joke: Women Speak of the Pain of Going Bald

"Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia," said FDA official Kendall Marcus in a statement. 

"Today's approval will help fulfill a significant unmet need for patients with severe alopecia areata."

Baricitinib, which is made by U.S. pharmaceutical company Eli Lilly and known by the trade name Olumiant, belongs to a class of drugs called Janus kinase inhibitors. It works by interfering with the cellular pathway that leads to inflammation.

Continue reading below ↓

Its approval for use against alopecia was based on the results of two randomized, controlled clinical trials involving a total 1,200 adults with severe alopecia.

Each trial split participants into three groups: a placebo group, a group that received a two-milligram dose every day, and a group that received a four-milligram dose every day.

After 36 weeks, almost 40% of those on the higher dose grew back 80% of their scalp hair, compared to around 23% of the lower dose group, and 5% of the placebo group.

Around 45% of people in the higher dose group also saw significant eyebrow and eyelash regrowth.

The most common side effects included upper respiratory tract infections, headaches, acne, high cholesterol, and increase of an enzyme called creatine phosphokinase.

Prior treatments for alopecia included topical or oral drugs, but these have been considered experimental and none was approved.

Baricitinib was previously approved for treatment of rheumatoid arthritis, and during the COVID-19 pandemic its license was extended to the treatment of hospitalized COVID-19 patients.

Continue reading below ↓
Recommended Videos

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
Here's what President Marcos Sr. said in his first SONA.
The president overcomes the disease for the second time.
With the reopening of several local destinations, this app has never been more timely.
Here's everything you need to know so far.
It records highest case load since May.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.